Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD) received the “Most Valuable Investment Award” at the 10th China Medical Industry Innovation Competition for its artificial intelligence operated surgical robot.
Announced on Monday, the system precisely ablates solid tumors like thyroid nodules, breast nodules, liver cancer, and lung cancer. Furthermore, Baird Medical’s AI Tumor Ablation Surgical Robot will be an intelligent surgical system using AI with robotic arm control.
Its key innovations will include autonomous decision making. Also, an AI-powered learning framework analyzes imaging, physiological data, and thermal field simulations to precisely adjust parameters.
The system will also feature a multi-technology synergy platform, integrating microwave, radiofrequency, laser, and nano-knife ablation technologies.
The AI can use alternative methods to overcome the limitations of traditional single-technique approaches. This includes perfect surgical site selection, nodule characteristics, energy output and ablation methods.
Additionally, the robot will provide intelligent automation to integrate preoperative 3D lesion segmentation. It also includes millimeter level path planning, and intraoperative micron level fully automated surgery, followed by predictive postoperative outcome analysis.
Surgeons will act as overseers, acting only at critical times in a passive mode as needed. This approach will significantly enhance efficiency.
Baird Medical’s proprietary AI-driven platform will also serve as the system’s “brain,” providing three key technological advantages.
It will establish an extensive medical knowledge base by including over 100,000 tumor ablation image cases and 50,000 pathology reports. This will enable cross modal data correlation and in depth analysis.
Read more: Breath Diagnostics pioneers novel lung cancer breath test
Read more: Breath Diagnostics takes aim at lung cancer with One Breath
Research and development involves three key pillars
The platform will also build a self improving learning architecture. It will use federated learning technology to share data across partner hospitals and reduce model repetition cycles to weeks.
This project will implement the company’s R&D strategy on three core pillars.
The first is a team of medical robotics experts from Nanyang Technological University. The second is a team of oncologic surgeons, and the third an engineering team from the Chinese Academy of Sciences.
This core team has deep expertise in AI-driven medical applications and has filed over 90 patents.
.
Follow Joseph Morton on Twitter
joseph@mugglehead.com
